Specifically designed by the Society for Immunotherapy of Cancer (SITC), the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CNE- and CPE-certified programs, presented by leading, local authorities in tumor immunology and cancer immunotherapy.
These six-hour programs will facilitate understanding of the clinical applications of immunotherapy for disease states with FDA-approved treatments; strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting; and the identification and management of immune-related adverse events.
Attendees will also have an opportunity for connecting with regional experts in the immunotherapy field at the in-person event, through two post-program webinars, and indefinitely through a dedicated online SITC CONNECT community forum.
SITC has partnered with the American Academy of Emergency Medicine (AAEM) and the Association of Community Cancer Centers (ACCC) to provide guidance for emergency physicians in identifying and managing patients who present to the ER with immune-related adverse events, and practical information about the necessary hospital operations for providing immunotherapy and strategies for obtaining reimbursement.
The target audience for ACI program series is patient care providers and others who wish to learn the basic principles of tumor immunology and immunotherapy, and to improve their ability to integrate immunotherapy into state-of-the-art clinical management for their patients. This intended audience includes clinical oncologists, registered nurses, nurse practitioners, pharmacists, emergency physicians, allied health professionals, other patient care providers, students and patient advocates.
The topics that will be covered during each program in the series are as follows:
ACI Registration Costs
Continuing Education Info
ACI Online Programs
ACI Enduring Materials
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com